Cannabinoid and Glutamate Systems May Jointly Disrupt Brain Oscillations in Psychosis

CB1 receptor agonists and NMDA receptor antagonists both reduce GABAergic signaling on interneurons, disrupting the theta and gamma brain oscillations that are critical for cognition - a potential shared mechanism underlying psychosis.

Sherif, Mohamed A et al.·The European journal of neuroscience·2018·Moderate EvidenceReview
RTHC-01836ReviewModerate Evidence2018RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Review
Evidence
Moderate Evidence
Sample
Not reported

What This Study Found

CB1Rs and NMDARs have direct and indirect interactions in brain regions implicated in schizophrenia (hippocampus, frontal cortex, cerebellum). Both systems converge on GABA interneurons: CB1R agonists and NMDAR antagonists each reduce GABAergic neurotransmission, leading to unsynchronized pyramidal neuron activity and disrupted neural oscillations involved in information processing.

Key Numbers

Theta oscillations (4-7 Hz) and gamma oscillations (30-80 Hz) are the key frequencies discussed. Three brain regions examined: hippocampus, frontal cortex, and cerebellum.

How They Did This

Review synthesizing literature on cannabinoid-glutamate interactions in the context of neural oscillations and schizophrenia, aiming to bridge the "cannabis model" and "ketamine model" of psychosis.

Why This Research Matters

Schizophrenia research has developed separate cannabinoid and glutamate models of the disorder. This review argues these are not competing explanations but complementary mechanisms that converge on disrupted brain oscillations, potentially explaining why cannabis use increases psychosis risk.

The Bigger Picture

Unifying the cannabinoid and glutamate models of schizophrenia could lead to more comprehensive treatment approaches that target the shared downstream effects rather than individual receptor systems.

What This Study Doesn't Tell Us

Largely theoretical synthesis. Much evidence comes from acute drug administration studies rather than chronic exposure. The relationship between oscillatory disruptions and clinical symptoms is complex and not fully understood.

Questions This Raises

  • ?Could combined CB1R and NMDAR modulation be more effective than targeting either system alone?
  • ?Do chronic cannabis users show the predicted oscillatory disruptions?
  • ?Could oscillatory measures serve as biomarkers for cannabis-related psychosis risk?

Trust & Context

Key Stat:
CB1R agonists and NMDAR antagonists both reduce GABA interneuron signaling, converging on the same disrupted brain oscillation patterns seen in schizophrenia.
Evidence Grade:
Moderate - well-reasoned theoretical synthesis of existing evidence, but largely speculative regarding combined mechanisms.
Study Age:
Published in 2018.
Original Title:
Cannabinoid-glutamate interactions and neural oscillations: implications for psychosis.
Published In:
The European journal of neuroscience, 48(8), 2890-2902 (2018)
Database ID:
RTHC-01836

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Summarizes existing research on a topic.

What do these levels mean? →

Frequently Asked Questions

How do cannabis and glutamate systems relate in the brain?

CB1 cannabinoid receptors and NMDA glutamate receptors interact directly and indirectly in key brain regions. Both systems affect GABA interneurons, and disrupting either one can produce similar effects on brain oscillations linked to psychosis.

What are brain oscillations and why do they matter for psychosis?

Brain oscillations are rhythmic patterns of neural activity (like theta at 4-7 Hz and gamma at 30-80 Hz) that coordinate information processing. Disrupted oscillations are consistently found in schizophrenia and may underlie cognitive symptoms.

Read More on RethinkTHC

Cite This Study

RTHC-01836·https://rethinkthc.com/research/RTHC-01836

APA

Sherif, Mohamed A; Cortes-Briones, Jose A; Ranganathan, Mohini; Skosnik, Patrick D. (2018). Cannabinoid-glutamate interactions and neural oscillations: implications for psychosis.. The European journal of neuroscience, 48(8), 2890-2902. https://doi.org/10.1111/ejn.13800

MLA

Sherif, Mohamed A, et al. "Cannabinoid-glutamate interactions and neural oscillations: implications for psychosis.." The European journal of neuroscience, 2018. https://doi.org/10.1111/ejn.13800

RethinkTHC

RethinkTHC Research Database. "Cannabinoid-glutamate interactions and neural oscillations: ..." RTHC-01836. Retrieved from https://rethinkthc.com/research/sherif-2018-cannabinoidglutamate-interactions-and-neural

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.